Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the US Food & Drug Administration (FDA) provided endorsement of the plans for the Phase IIb trial of CS1 as noted by the official meeting minutes from the Type C-meeting held on April 21. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial aiming to further eval

Fresenius Management Board with Wolfgang Kirsch, Chairman of the Supervisory Board (third from left) Download Image (JPG 2.76 MB) Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Annual General Meeting 2025 Contact Timo Lindemann T +49 (0) 6172 608-7939 timo.lindemann@fresenius.com Documents Text as PDF document (PDF, 79 KB) The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger compan

Pictured: GSK’s headquarters in West London/iStock iStock, Magdalena Wygralak The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD for their blockbuster antibody Dupixent. After failing to meet its target decision date earlier this month, the FDA on Thursday approved the expansion of GSK ’s anti-IL-5 antibody Nucala to cover chronic obstructive pulmonary disease. The approval opens up the use of Nucala to patients with

iStock, beast01 Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the first-line setting for this indication. Merus’ investigational bispecific antibody petosemtamab, when combined with Merck’s mega-blockbuster Keytruda, led to a nearly 80% overall survival rate when used as a frontline treatment option for certain patients with head and neck cancer, according to a Phase II readout posted Thursday. Writing to investors early o

iStock, May Lim The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines. The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously on Thursday for a monovalent COVID-19 shot that includes coverage of the virus’ JN.1 lineage, the same recommendation it made last year. But looming over Thursday’s discussions—Leerink analysts in a note called it “the elephant in the room—was the FDA’s recently announ

VANCOUVER, May 23rd, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, and Luvo Medical Technologies Inc. (“Luvo”), today announce the signing of an Asset Purchase Agreement for the sale of Zimed® PF (the “Transaction”). Unless otherwise noted, all figures are in Canadian currency. “Since Zimed® PF was launched in 2023 in collaborat

ISLAMABAD, May 22, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). The collaboration will see the deployment of Chiron and Ava-AutoNarrator™—two proprietary, AGI-powered agents—across IDC's core diagnostic workflows. Continue Reading Belal Faruki, CEO of MindHYVE.ai™, an

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025 Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan expected to follow as part of global study start-up SAN DIEGO, May 22, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it will present a Trial in Progress poster at the 2025 America

RESEARCH TRIANGLE PARK, N.C., May 22, 2025 /PRNewswire/ -- Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that its Trial in Progress abstract has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, which is being held May 30 – June 3, 2025 at the McCormick Place Convention Center in Chicago, Illinois. The poster will highlight the company's ongo

COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product Photos Summary Company Announcement Date: May 21, 2025 FDA Publish Date: May 22, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description The product contains undeclared Dexamethasone, Diclofenac and Omeprazole Company Name: UMARY USA Brand